Home Compare ERF.PA vs WST
Stock Comparison · Comparison

Eurofins Scientific vs West Pharmaceutical Services: Which Stock Looks Stronger in 2026?

West Pharmaceutical Services holds the cleaner structural position, with profitability as the main driver and growth adding further support. Eurofins Scientific SE does not offset that deficit through any equally strong structural edge elsewhere. In the market, Eurofins Scientific SE carries the stronger setup — intact trend against West Pharmaceutical Services's broken trend. That leaves a split case: the structural lead stays with West Pharmaceutical Services, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Profitability remains the main source of distance in the comparison. The overall score gap is 26 points in favour of West Pharmaceutical Services, Inc..

Trajectory Similarity
0.73
Similar
Peer-set rank: #8
within Eurofins Scientific SE's functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.

Most of the shared profile comes through revenue growth trajectory and capital structure.

Similarity drivers
revenue growth trajectorycapital structure
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
ERF.PA
Eurofins Scientific SE
41
Peer-Score
Signal qualityHigh
vs
WST
West Pharmaceutical Services, Inc.
67
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: ERF.PA vs WST Profitability 19 84 Stability 54 50 Valuation 49 61 Growth 50 66 ERF.PA WST
Gap Ranking
#1 Profitability +65
#2 Growth +16
#3 Valuation +12
#4 Stability +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ERF.PA and WST Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ERF.PAWST Relative valuation Structural strength

The setup stays mixed because structure and the price setup do not align cleanly in one direction.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
On profitability, West Pharmaceutical Services, Inc. ranks near the top of the group; Eurofins Scientific SE sits in the weaker half.
Growth
On growth, the edge still sits with West Pharmaceutical Services, Inc., even though both profiles look solid.
Profitability — Dominant Gap
ERF.PA
19
WST
84
Gap+65in favour of WST

The profitability lead is mainly driven by a 8.4-point operating margin advantage.

What keeps the gap from being one-sided

Eurofins Scientific SE still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

Profitability is the clearest driver, and growth also supports West Pharmaceutical Services, Inc.'s broader structural position.

Explore full peer positioning in AssetNext

Break down the ERF.PA vs WST comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-driven comparisons

Explore how ERF.PA and WST each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.